NFG
TGTX icon

Norris Financial Group’s TG Therapeutics TGTX Stock Holding History

Norris Financial Group’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-14,917
Closed -$265K – 87
2024
Q2 		$265K Sell
14,917
-467
-3% -$7.45K 0.14% 66
2024
Q1 		$234K Sell
15,384
-1,033
-6% -$16.5K 0.13% 68
2023
Q4 		$280K Buy
16,417
+4,263
+35% +$49.5K 0.17% 55
2023
Q3 		$102K Buy
+12,154
New +$169K 0.07% 61
2023
Q2 		– Sell
-26,913
Closed -$405K – 73
2023
Q1 		$405K Sell
26,913
-6,591
-20% -$100K 0.3% 49
2022
Q4 		$396K Buy
33,504
+1,602
+5% +$11.6K 0.34% 50
2022
Q3 		$189K Buy
31,902
+3,845
+14% +$25.2K 0.17% 62
2022
Q2 		$119K Buy
28,057
+3,328
+13% +$20.8K 0.1% 62
2022
Q1 		$235K Buy
24,729
+9,309
+60% +$108K 0.14% 69
2021
Q4 		$293K Buy
15,420
+6,586
+75% +$171K 0.18% 68
2021
Q3 		$294K Buy
+8,834
New +$273K 0.19% 67
2021
Q2 		– Sell
-4,580
Closed -$221K – 89
2021
Q1 		$221K Buy
+4,580
New +$220K 0.16% 71

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Norris Financial Group's TGTX Position: Q3 2024 in Review

Norris Financial Group sold out of TG Therapeutics (TGTX) in Q3 2024, closing a stake of 14,917 shares — an estimated $265K sold.

Norris Financial Group first reported a position in TGTX in Q1 2021 and held it in 12 quarters. The position peaked at $405K in Q1 2023. 308 funds tracked by Wall St. Rank hold TGTX as of Q3 2024.

  • Norris Financial Group reported no remaining TG Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Norris Financial Group sold 14,917 TG Therapeutics shares in Q3 2024, an estimated $265K.
  • Norris Financial Group first reported a position in TG Therapeutics in Q1 2021 and held it in 12 quarters.
  • Norris Financial Group's TG Therapeutics position peaked at $405K in Q1 2023.
  • 308 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2024.

Based on Norris Financial Group's 13F filing for Q3 2024, filed 20 May 2026.